3,087 Shares in Labcorp Holdings Inc. $LH Purchased by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. bought a new position in shares of Labcorp Holdings Inc. (NYSE:LH) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,087 shares of the medical research company’s stock, valued at approximately $774,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC purchased a new stake in Labcorp in the fourth quarter valued at approximately $991,000. Integrated Wealth Concepts LLC increased its holdings in shares of Labcorp by 7.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock worth $565,000 after buying an additional 177 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Labcorp by 52.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock valued at $82,353,000 after buying an additional 121,304 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Labcorp during the 2nd quarter worth $5,873,000. Finally, First Trust Advisors LP lifted its holdings in shares of Labcorp by 83.2% during the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock worth $22,588,000 after acquiring an additional 39,087 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Labcorp Stock Up 0.0%

Shares of Labcorp stock opened at $270.81 on Monday. The company has a 50-day moving average of $273.67 and a 200 day moving average of $268.17. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72. The firm has a market cap of $22.26 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.85 and a beta of 1.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.56 billion. During the same quarter in the previous year, the business posted $3.45 EPS. Labcorp’s revenue was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, sell-side analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp’s payout ratio is 27.53%.

Insider Activity at Labcorp

In related news, EVP Der Vaart Sandra D. Van sold 548 shares of Labcorp stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the sale, the executive vice president owned 2,579 shares of the company’s stock, valued at $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Brian J. Caveney sold 1,500 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the sale, the executive vice president directly owned 30,107 shares of the company’s stock, valued at $8,619,935.17. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 in the last quarter. 0.84% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on LH shares. Robert W. Baird boosted their target price on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Piper Sandler upped their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Finally, Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $307.20.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.